MX346424B - Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa. - Google Patents
Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa.Info
- Publication number
- MX346424B MX346424B MX2013001172A MX2013001172A MX346424B MX 346424 B MX346424 B MX 346424B MX 2013001172 A MX2013001172 A MX 2013001172A MX 2013001172 A MX2013001172 A MX 2013001172A MX 346424 B MX346424 B MX 346424B
- Authority
- MX
- Mexico
- Prior art keywords
- dry powder
- powder formulation
- phosphodiesterase inhibitor
- relates
- phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se relaciona con una formulación farmacéutica en la forma de un polvo seco inhalable que comprende partículas de un inhibidor de fosfodiesterasa-4 como ingrediente activo. La invención también se relaciona con el proceso para preparar la formulación y con su uso en la prevención y/o el tratamiento de una enfermedad respiratoria tal como asma y EPOC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10171748 | 2010-08-03 | ||
PCT/EP2011/062872 WO2012016889A2 (en) | 2010-08-03 | 2011-07-27 | Dry powder formulation comprising a phosphodiesterase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013001172A MX2013001172A (es) | 2013-03-07 |
MX346424B true MX346424B (es) | 2017-03-21 |
Family
ID=43262631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001172A MX346424B (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa. |
Country Status (36)
Country | Link |
---|---|
US (2) | US9132121B2 (es) |
EP (2) | EP2600830B1 (es) |
JP (1) | JP6004233B2 (es) |
KR (1) | KR101805958B1 (es) |
CN (2) | CN103052379A (es) |
AR (1) | AR082443A1 (es) |
AU (1) | AU2011287711B2 (es) |
BR (1) | BR112013002506A2 (es) |
CA (1) | CA2807256C (es) |
CL (1) | CL2013000293A1 (es) |
CO (1) | CO6690744A2 (es) |
CY (1) | CY1120605T1 (es) |
DK (1) | DK2600830T3 (es) |
EA (2) | EA027692B1 (es) |
ES (1) | ES2664175T3 (es) |
GE (1) | GEP20156343B (es) |
HR (1) | HRP20180717T1 (es) |
HU (1) | HUE037620T2 (es) |
IL (1) | IL224517B (es) |
LT (1) | LT2600830T (es) |
MA (1) | MA34449B1 (es) |
ME (1) | ME03022B (es) |
MX (1) | MX346424B (es) |
MY (1) | MY179703A (es) |
NO (1) | NO2600830T3 (es) |
NZ (1) | NZ606548A (es) |
PE (2) | PE20171256A1 (es) |
PL (1) | PL2600830T3 (es) |
PT (1) | PT2600830T (es) |
RS (1) | RS57061B1 (es) |
SG (1) | SG187258A1 (es) |
SI (1) | SI2600830T1 (es) |
TR (1) | TR201807012T4 (es) |
UA (1) | UA112296C2 (es) |
WO (1) | WO2012016889A2 (es) |
ZA (1) | ZA201300870B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
RU2578975C2 (ru) | 2010-08-03 | 2016-03-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы |
CN103562185A (zh) | 2011-06-06 | 2014-02-05 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
US20160030435A1 (en) * | 2013-03-15 | 2016-02-04 | Robert I HENKIN | Phosphodiesterase inhibitor treatment |
US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
CN110256338A (zh) | 2013-10-22 | 2019-09-20 | 奇斯药制品公司 | 用于制备pde4抑制剂的方法 |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
TR201818680T4 (tr) | 2014-07-09 | 2019-01-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | İnhalasyona yönelik formülasyonların hazırlanması için bir proses. |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
KR101859750B1 (ko) * | 2017-09-13 | 2018-05-21 | 제일에스엠피(주) | 고정식 열 저장 운반장치 |
KR101859752B1 (ko) * | 2017-09-13 | 2018-05-21 | 심원 | 조립식 열 저장 운반장치 |
WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062006A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062005A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
DE59801018D1 (de) | 1997-09-16 | 2001-08-16 | Trench Switzerland Ag Basel | Spannungsteiler |
TR200102567T2 (tr) | 1999-03-05 | 2002-01-21 | Chiesi Farmaceutici S.P.A. | İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
ES2359576T5 (es) | 2002-07-31 | 2020-03-03 | Chiesi Farm Spa | Inhalador de polvo |
DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
KR100956703B1 (ko) * | 2005-06-06 | 2010-05-06 | 에프. 호프만-라 로슈 아게 | 간 카르니틴 팔미토일 전이효소(l-cpt1) 저해제로서유용한 설폰아마이드 유도체 |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
RU2578975C2 (ru) | 2010-08-03 | 2016-03-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы |
CN103562185A (zh) | 2011-06-06 | 2014-02-05 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
CN110256338A (zh) | 2013-10-22 | 2019-09-20 | 奇斯药制品公司 | 用于制备pde4抑制剂的方法 |
-
2011
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 CA CA2807256A patent/CA2807256C/en active Active
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/me unknown
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/en active Active
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/en active Application Filing
- 2011-07-27 SI SI201131448T patent/SI2600830T1/en unknown
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active IP Right Grant
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 EP EP17176635.5A patent/EP3246016A1/en active Pending
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
- 2018-05-09 HR HRP20180717TT patent/HRP20180717T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY179703A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
IL231226A (en) | Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases | |
GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
MX2012012438A (es) | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. | |
IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
WO2011152804A3 (en) | Process for dry powder formulations | |
PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
TR201000733A2 (tr) | Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler. | |
IL225105A (en) | Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs | |
WO2011093818A3 (en) | Pharmaceutical compositions comprising salmeterol and fluticasone | |
WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
WO2012030308A3 (en) | Formulation comprising cellobiose | |
WO2013038200A3 (en) | Neurodevelopmental disorders | |
WO2011093811A3 (en) | Pharmaceutical preparations comprising formoterol and fluticasone | |
TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
WO2013153349A3 (en) | Pharmaceutical composition comprising arformoterol and fluticasone furoate | |
WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
WO2011093814A3 (en) | A pharmaceutical combination comprising formoterol and ciclesonide | |
PH12015501179A1 (en) | Fixed dose pharmaceutical composition comprising mometasone and azelastine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |